1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019

Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019

  • November 2019
  • 237 pages
  • ID: 5830781
  • Format: PDF
  • By Global Markets Direct

Summary

Table of Contents

Search Inside

Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019

Summary
According to the recently published report ’Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019’; Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 64 molecules. Out of which approximately 63 molecules are developed by companies and remaining by the universities/institutes.

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses.

The report ’Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019’ outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 8, 17, 1, 25 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology and Infectious Disease which include indications Solid Tumor, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Breast Cancer, Colon Cancer, Gastric Cancer, Renal Cell Carcinoma, Small-Cell Lung Cancer, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Cervical Cancer, Metastatic Breast Cancer, Nasopharyngeal Cancer, Squamous Non-Small Cell Lung Cancer, Bladder Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Anal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Gastroesophageal (GE) Junction Carcinomas, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Non-Hodgkin Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer, Endometrial Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Germ Cell Tumors, Lung Cancer, Lymphoma, Malignant Pleural Mesothelioma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Salivary Gland Cancer, Sarcomas, Triple-Negative Breast Cancer (TNBC), Vaginal Cancer, Vulvar Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenoid Cystic Carcinoma (ACC), Adrenal Gland Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Basal Cell Carcinoma (Basal Cell Epithelioma), Bone Sarcoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Dysgerminoma, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Ewing Sarcoma, Follicular Thyroid Cancer, Gallbladder Cancer, Germinomatous (Seminomatous) Germ Cell Tumors, Glioblastoma Multiforme (GBM), Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kaposi Sarcoma, Leukemia, Liver Cancer, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medulloblastoma, Meningioma, Metastatic Biliary Tract Cancer, Metastatic Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Metastatic Uveal Melanoma, Non-Small Cell Lung Carcinoma, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor (PNET), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer, Urinary Tract Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Rectal Cancer - Pipeline Review, H2 2019

Rectal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Rectal Cancer - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Pipeline Review, H2 2019, provides an overview of the Rectal Cancer (Oncology) ...

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019SummaryCellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 27 molecules. ...

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2019

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on